Tal Teitz, PhD
Tal Teitz, PhD

Tal Teitz, PhD

Assistant Professor
School of Medicine

Academic Appointments


  • Pharmacology and Neuroscience


  • Assistant Professor


Publications and Presentations


  • Abstract
    There are currently no FDA-approved therapies to prevent the hearing loss associated with the usage of cisplatin in chemotherapeutic regimens. We recently demonstrated that the pharmacologic inhibition with kenpaullone or genetic deletion of CDK2 preserved hearing function in animal models treated with cisplatin, which suggests that CDK2 is a promising therapeutic target to prevent cisplatin-induced ototoxicity. In this study, we identified two lead compounds, AT7519 and AZD5438, from a focused library screen of 187 CDK2 inhibitors, performed in an immortalized cell line derived from neonatal mouse cochleae treated with cisplatin. Moreover, we screened 36 analogues of AT7519 and identified analogue 7, which exhibited an improved therapeutic index. When delivered locally, analogue 7 and AZD5438 both provided significant protection against cisplatin-induced ototoxicity in mice. Thus, we have identified two additional compounds that prevent cisplatin-induced ototoxicity in vivo and provided further evidence that CDK2 is a druggable target for treating cisplatin-induced ototoxicity., Journal of Medicinal Chemistry, volume 61(17), 7700-7709, 2018


  • Abstract for Meeting: Development of Small Molecule Protein Kinase Inhibitors for Hearing Protection (last author), ARO annual Meeting, 42nd ARO Annual Meeting, 44, 2019


  • Gave a presentation in the 5th Chinese Hearing Research Conference on our research studies , Beijing, China 2019, titled "Drug Development for Cisplatin- and Noise- induced Hearing Loss.", 2019
  • Research Rounds and Seminars at Department of Pharmacology and Neuroscience, 2019